Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer

Leonardo Mirandola, Yuefei Yu, Martin J. Cannon, Marjorie R. Jenkins, Rakhshanda L. Rahman, Diane D. Nguyen, Fabio Grizzi, Everardo Cobos, Jose A. Figueroa, Maurizio Chiriva-Internati

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Objective. Ovarian cancer is the most deadly gynecologic malignancy worldwide. Since the pathogenesis of ovarian cancer is incompletely understood, and there are no available screening techniques for early detection, most patients are diagnosed with advanced, incurable disease. In an effort to develop innovative and effective therapies for ovarian cancer, we tested the effectiveness of Galecti-3C in vitro. This is a truncated, dominant negative form of Galectin-3, which is thought to act by blocking endogenous Galectin-3. Methods. We produced a truncated, dominant-negative form of Galectin-3, namely Galetic-3C. Ovarian cancer cell lines and primary cells from ovarian cancer patients were treated with Galectin-3C, and growth, drug sensitivity, and angiogenesis were tested. Result. We show, for the first time, that Galectin-3C significantly reduces the growth, motility, invasion, and angiogenic potential of cultured OC cell lines and primary cells established from OC patients. Conclusions. Our findings indicate that Galectin-3C is a promising new compound for the treatment of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)573-579
Number of pages7
JournalGynecologic Oncology
Issue number3
StatePublished - Dec 1 2014
Externally publishedYes


  • Angiogenesis
  • Galectin-3
  • Galectin-3C
  • Invasion
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer'. Together they form a unique fingerprint.

Cite this